Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Wang et al. and Shen et al.

Journal of the National Cancer Institute·2026
Same author

Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Distinct neuronal, proliferative, and secretory pathways are perturbed in cancer survivors with depressive symptoms.

medRxiv : the preprint server for health sciences·2026
Same author

<i>Supportive Care in What</i>? Myths and Misconceptions That Prevent the Provision of Excellent Cancer Care.

JCO global oncology·2026
Same author

Trajectory and predictors of cancer- and treatment-related fatigue (CRF) in adolescent and young adult cancer patients: a prospective, longitudinal study.

BMC cancer·2026
Same author

Catalpol reverses doxorubicin-induced cognitive decline, neuroinflammation, and restores synaptic integrity.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same journal

The use of natural language processing in predictive toxicology.

Expert opinion on drug metabolism & toxicology·2026
Same journal

An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Optimizing tamoxifen therapy in breast cancer: a narrative review of dose escalation in patients with CYP2D6 polymorphisms.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a physiologically based pharmacokinetic (PBPK) modeling approach.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Gastrointestinal bleeding risk among antithrombotics users: a propensity score matched study of drug classes.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Complex <i>in vitro</i> model developers' perspective on advanced hepatic <i>in vitro</i> culture methods for predictive drug safety.

Expert opinion on drug metabolism & toxicology·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Clinically-relevant anticancer-antidepressant drug interactions.

Alexandre Chan1, Terence Rong De Ng, Kevin Yi-Lwern Yap

  • 1National University of Singapore, Faculty of Science, Department of Pharmacy, Block S4, 18 Science Drive 4, 117543, Singapore.

Expert Opinion on Drug Metabolism & Toxicology
|December 24, 2011
PubMed
Summary
This summary is machine-generated.

Anticancer drugs (ACD) and antidepressants (AD) can interact in cancer patients, impacting outcomes. This review details these drug-drug interactions (DDIs) to aid oncologists in managing patient care.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 26, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Depression frequently co-occurs with cancer.
  • Concurrent use of anticancer drugs (ACD) and antidepressants (AD) poses risks of drug interactions.
  • These interactions can negatively affect patient outcomes and quality of life.

Purpose of the Study:

  • To review potential anticancer-antidepressant drug (ACD-AD) interactions in cancer patients.
  • To provide oncology practitioners with tumor-type-specific drug-drug interaction (DDI) information.

Main Methods:

  • Systematic review of existing literature on ACD-AD interactions.
  • Categorization of DDIs by specific tumor types.

Main Results:

  • Discussion of clinically significant ACD-AD DDIs relevant to various cancer types.
  • Identification of the need for specialized DDI databases in oncology.

Conclusions:

  • Current oncology-specific DDI databases are limited.
  • Development of consolidated databases like OncoRx can streamline DDI searches.
  • Future advancements in epigenetic therapy and semantic web technology may enhance DDI detection and improve cancer patient pharmaceutical care.